Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 324

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 324
---
 Combination. In part because the PIPE Investment
was not consummated (a more detailed discussion of this agreement is included in Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources”) we will be required
to seek additional financing to provide such operating capital. We cannot assure you that such financing will be available on acceptable
terms, if at all. We may require such financing to fund the operations or growth of the Company. The failure to secure additional financing
could have a material adverse effect on the continued development or growth of the Company. None of the Company’s Sponsor, officers,
directors or their affiliates is required to provide any financing to us in connection with or after the Business Combination. If they
elect to do so, their additional contributions of capital to the Company may require them to first sell a portion of their founders shares
or other Company common stock holdings in qualified insider transactions, which may impact the market price levels of Company common stock.

We will require additional capital to fund our operations, and
if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates.

We expect to spend substantial capital to complete the development
of, seek regulatory approvals for and commercialize our pharmaceutical product candidates. We are unable to estimate the actual funds
we will require to execute on our strategy because the length of time and activities associated with successful development of our pharmaceutical
product candidates is highly uncertain, and due to the inherent challenges and uncertainties associated with the development of novel
healthcare technologies.

45

The additional capital that we need to fund our operations may
not be available at all, or on terms that allow us to continue operations or provide any hope of generating future profits.

We cannot be certain that additional capital will be available on acceptable
terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly
delay, scale back or discontinue the development or commercialization of any product candidate, delay the launch or expansion of a given
product or potentially discontinue our operations altogether. In addition, attempting to secure additional capital may divert the time
and attention of our management from day-to-day activities and harm our business. Because of the numerous risks and uncertainties
associated with our business, we are unable to estimate the amounts of increased capital outlays, operating expenditures and capital requirements
associated with our current product development programs